Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aussie Chemgenex Licenses Leukemia Drug To Support U.S. Push

This article was originally published in PharmAsia News

Executive Summary

Australia's Chemgenex has signed a deal with U.S.-based Hospira that could be worth $119.4 million to the Australian firm by the time it runs its course

You may also be interested in...



Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals

WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage

French Agency Sets Up New Body To Advise On Biosimilar Substitution

The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.

New EU Regulation Extending IVD Deadlines Expected In April

IVD manufacturers look set to be granted up to 18 more months to comply with the EU IVD Regulation very soon.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel